Adenosine A2a Receptor Protein

📖 Wiki Page

protein979 wordssynced 2026-04-02

Adenosine A2a Receptor Protein (ADORA2A)

...

Adenosine A2a Receptor Protein (ADORA2A)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Adenosine A2a Receptor Protein</th>
</tr>
<tr>
<td class="label">Ligand Type</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">Antagonists</td>
<td>Istradefylline, Caffeine, SCH58261</td>
</tr>
<tr>
<td class="label">Agonists</td>
<td>CGS21680, Regadenoson</td>
</tr>
<tr>
<td class="label">Allosteric modulators</td>
<td>VCP746</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Striatum (Caudate/Putamen)</td>
<td>Very High</td>
</tr>
<tr>
<td class="label">Nucleus Accumbens</td>
<td>High</td>
</tr>
<tr>
<td class="label">Olfactory Bulb</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Hippocampus](/brain-regions/hippocampus)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">[Cortex](/brain-regions/cortex)</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">Thalamus</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Pathway Signaling Pathways</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">MAPK/ERK</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">PI3K/AKT</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">[NF-κB](/entities/nf-kb)</td>
<td>Modulation</td>
</tr>
<tr>
<td class="label">β-arrestin</td>
<td>Recruitment</td>
</tr>
<tr>
<td class="label">Condition</td>
<td>Role</td>
</tr>
<tr>
<td class="label">Depression</td>
<td>Anhedonia, motivation</td>
</tr>
<tr>
<td class="label">Anxiety</td>
<td>Stress response</td>
</tr>
<tr>
<td class="label">Cancer</td>
<td>Immunosuppression</td>
</tr>
<tr>
<td class="label">Stroke</td>
<td>Neuroprotection</td>
</tr>
<tr>
<td class="label">Huntington's Disease</td>
<td>Motor symptoms</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Approval</td>
</tr>
<tr>
<td class="label">Istradefylline (Nourianz)</td>
<td>2019</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Tozadenant</td>
<td>Biotie</td>
</tr>
<tr>
<td class="label">Preladenant</td>
<td>Merck</td>
</tr>
<tr>
<td class="label">ST1535</td>
<td>Sigma-[Tau](/proteins/tau)</td>
</tr>
<tr>
<td class="label">Vipadenant</td>
<td>Vicore</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/neurodegeneration" style="color:#ef9a9a">neurodegeneration</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-41bc2d38" style="color:#ce93d8" title="Score: 0.52">Adenosine-Astrocyte Metabolic Reset...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">65 edges</a></td>
</tr>
</table>

Introduction

Adenosine A2A Receptor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Adenosine A2a receptor (A2AR, ADORA2A) is a Gs protein-coupled receptor that stimulates adenylate cyclase activity, increasing intracellular cAMP levels. A2AR is highly enriched in the striatum (caudate nucleus and putamen) where it plays a critical role in modulating motor control, reward processing, and habit formation. This receptor has emerged as a major therapeutic target for [Parkinson's disease](/diseases/parkinsons-disease), with the A2AR antagonist istradefylline (Nourianz) FDA-approved as an adjunct therapy. Beyond PD, A2AR modulators are being investigated for [Alzheimer's disease](/diseases/alzheimers-disease), schizophrenia, depression, and cancer immunotherapy.

Structure and Pharmacology

Receptor Architecture

A2AR is a typical GPCR with seven transmembrane domains:

N-terminal extracellular domain: Contains glycosylation sites
Seven transmembrane helices (TM1-TM7): Form the ligand-binding pocket
Intracellular loops (ICL1-3): Couple to G-proteins
C-terminal intracellular tail: Contains phosphorylation sites and palmitoylation

Ligand Binding

Structural Features

Key structural elements:

Conserved DRY motif: Critical for G-protein coupling
Ball-and-chain intracellular helix 8: Regulates desensitization
Disulfide bond: Stabilizes extracellular loops
Glycosylation: N-terminal ASN residues

Expression Pattern

Brain Distribution

A2AR shows highly region-specific expression:

Cellular Localization

Medium spiny [neurons](/entities/neurons) (MSNs): Highest density on D2-expressing MSNs
Glial cells: [Astrocytes](/entities/astrocytes) and [microglia](/entities/microglia) express A2AR
Endothelial cells: Vascular A2AR regulate blood flow
Immune cells: T cells, B cells, macrophages

Signaling Mechanisms

Primary Signaling Pathway

A2AR activates Gs/olf proteins leading to:

Adenylate cyclase activation → ↑ cAMP

Protein kinase A (PKA) activation → Phosphorylation of substrates

CREB activation → Gene transcription

PKA phosphorylation of DARPP-32 → Modulation of striatal signaling

Secondary

Cross-talk with Dopamine

A2AR-D2R interaction is crucial in striatum:

Antagonistic relationship: A2AR activation reduces D2R signaling
Heteromer formation: A2AR-D2R receptor complexes
Therapeutic implications: A2AR blockade enhances D2R function

Disease Associations

Parkinson's Disease

A2AR is the primary therapeutic target in PD:

Mechanism: A2AR overactivity in PD reduces motor function
Therapeutic strategy: A2AR antagonists restore dopaminergic tone
Clinical use: Istradefylline as add-on to levodopa
Benefits: Reduced "off" time, improved "on" time

Alzheimer's Disease

Emerging evidence for A2AR involvement:

Neuroinflammation: A2AR on [microglia](/cell-types/microglia-neuroinflammation) modulates inflammation
Amyloid pathology: A2AR affects [Aβ](/proteins/amyloid-beta) clearance
Memory function: Hippocampal A2AR regulates memory
Therapeutic potential: A2AR modulators in development

Schizophrenia

A2AR dysfunction implicated in schizophrenia:

Dopamine hypothesis interaction: Striatal A2AR-D2R balance
Cognitive deficits: Prefrontal A2AR modulation
Negative symptoms: Possible therapeutic benefit
Genetic associations: ADORA2A polymorphisms linked to schizophrenia

Other Conditions

Therapeutic Targeting

FDA-Approved Therapies

Clinical Pipeline

Challenges in Drug Development

Peripheral vs central effects: Limiting side effects

Species differences: Rodent vs human receptor pharmacology

[Blood-brain barrier](/entities/blood-brain-barrier) penetration: Required for CNS indications

Cardiovascular safety: A2AR in heart and vasculature

Animal Models

Knockout Studies

Adora2a-/- mice: Resistant to A2AR agonist effects
Conditional KO: Brain-specific deletion
Humanized mice: Express human A2AR

Phenotypic Findings

Enhanced D2R signaling
Reduced parkinsonian symptoms
Altered reward processing
Modified inflammatory responses

Disease Models

6-OHDA lesions: A2AR antagonists protect
MPTP toxicity: Modulation of neurodegeneration
Transgenic models: [α-synuclein](/proteins/alpha-synuclein) overexpression

Research Directions

Receptor structure: Cryo-EM of A2AR-G protein complexes

Heteromer biology: A2AR-D2R and A2AR-A1R complexes

Biomarkers: PET ligands for A2AR imaging

Immunotherapy: A2AR antagonists in cancer

Gene therapy: Viral vector delivery approaches

Background

The study of Adenosine A2A Receptor Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[1]: https://pubmed.ncbi.nlm.nih.gov/10629201/ PMID: 10629201(https://pubmed.ncbi.nlm.nih.gov/10629201/) - A2a adenosine receptor
[2]: https://pubmed.ncbi.nlm.nih.gov/10816402/ PMID: 10816402(https://pubmed.ncbi.nlm.nih.gov/10816402/) - Striatal A2a receptors
[3]: https://pubmed.ncbi.nlm.nih.gov/15604288/ PMID: 15604288(https://pubmed.ncbi.nlm.nih.gov/15604288/) - Parkinson's disease therapy
[4]: https://pubmed.ncbi.nlm.nih.gov/17585956/ PMID: 17585956(https://pubmed.ncbi.nlm.nih.gov/17585956/) - A2a receptor structure
[5]: https://pubmed.ncbi.nlm.nih.gov/19029120/ PMID: 19029120(https://pubmed.ncbi.nlm.nih.gov/19029120/) - Therapeutic potential
[6]: https://pubmed.ncbi.nlm.nih.gov/20139464/ PMID: 20139464(https://pubmed.ncbi.nlm.nih.gov/20139464/) - Clinical trials in PD
[7]: https://pubmed.ncbi.nlm.nih.gov/23452928/ PMID: 23452928(https://pubmed.ncbi.nlm.nih.gov/23452928/) - A2a-D2a receptor interaction
[8]: https://pubmed.ncbi.nlm.nih.gov/25872154/ PMID: 25872154(https://pubmed.ncbi.nlm.nih.gov/25872154/) - Neuroinflammation

External Links

[UniProt: ADORA2A](https://www.uniprot.org/uniprot/P29274)
[PDB: A2a Receptor](https://www.rcsb.org/structure/5G53)
[GeneCards: ADORA2A](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ADORA2A)
[OMIM: ADORA2A](https://www.omim.org/entry/102776)
[IUPHAR: A2a Receptor](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=12)

📖 View canonical wiki page →

Adenosine A2a Receptor Protein

Adenosine A2a Receptor Protein (ADORA2A)

Adenosine A2a Receptor Protein (ADORA2A)

Introduction

Overview

Structure and Pharmacology

Receptor Architecture

Ligand Binding

Structural Features

Expression Pattern

Brain Distribution

Cellular Localization

Signaling Mechanisms

Primary Signaling Pathway

Secondary

Cross-talk with Dopamine

Disease Associations

Parkinson's Disease

Alzheimer's Disease

Schizophrenia

Other Conditions

Therapeutic Targeting

FDA-Approved Therapies

Clinical Pipeline

Challenges in Drug Development

Animal Models

Knockout Studies

Phenotypic Findings

Disease Models

Research Directions

Background

References

See Also

External Links